CAR-T eligibility: how the treatment team assesses your case

Match the diagnosis to a specific product

The first question is which CAR-T product is being considered. Products target particular proteins and have approved uses for defined cancers, age groups and treatment histories. A diagnosis of lymphoma or leukemia needs to be narrowed to the exact subtype before the team can assess fit.

Bring the pathology and any flow-cytometry or molecular reports. If you have already received a treatment directed at the same target, include its name and response. Ask whether the current sample is sufficient or whether the team needs updated testing to understand the disease now.

Sources and references: [1] [2] [3]

Reconstruct the earlier treatment lines

Eligibility often depends on earlier medicines and the way the cancer responded. A line of therapy can contain several drugs, with maintenance continuing the same overall strategy. Counting drug names alone can therefore give the wrong picture.

For each regimen, list when it began, when it ended, the best response and the reason for stopping. Include transplant and any prior cellular therapy. For myeloma, for example, product requirements distinguish exposure to proteasome inhibitors, immunomodulatory medicines and anti-CD38 antibodies, and may specify resistance to lenalidomide. Your hematologist can confirm the line count.

Sources and references: [4] [5]

Consider whether preparation can happen in time

Autologous CAR-T requires cell collection and manufacturing. The team assesses how quickly the cancer is progressing and whether treatment can control it during that interval. A person with rapidly worsening symptoms may need an immediate disease-control plan while the CAR-T assessment continues.

Ask what would make the team proceed now, give bridging treatment first or choose another option. Recent scans, blood-test trends and a clear description of symptoms help answer that question. Tell the team if your condition has changed since the records were sent.

Sources and references: [1] [5]

Review organ function and infection carefully

Assessment may include heart, lung, kidney and liver function, blood counts and infection screening. The aim is to understand how you are likely to tolerate preparatory chemotherapy, immune reactions and the recovery period. An active infection may need treatment before CAR-T can proceed.

Age is considered alongside fitness and other health conditions. Describe what you can do day to day and what support you need. A detailed review is more useful than assuming one birthday or one laboratory result determines every product's eligibility. Ask which finding needs improvement or further assessment.

Sources and references: [5] [2]

Check the feasibility of collecting and preparing cells

The center reviews the timing of previous medicines and whether enough suitable T cells can be collected. It also plans venous access and the collection appointment. Some medicines require a specified interval before collection or treatment, so ask for a written schedule.

Continue to coordinate changes through the treating team. If another doctor proposes a new medicine while you are waiting, tell the CAR-T service so it can consider the effect on collection and timing. Also ask how the center handles an inadequate collection or a manufacturing delay.

Sources and references: [5] [6]

Caregiver and follow-up arrangements are part of readiness

You may need a caregiver, nearby accommodation and rapid access to the center after infusion. Neurological effects can make it difficult to recognize or communicate your own symptoms, so the support plan matters medically as well as practically.

Ask how long the center expects you to remain nearby, which visits are mandatory and what restrictions apply to driving. These details depend on the product and local protocol. For overseas treatment, discuss language needs, emergency transport and who will take over follow-up when you return home.

Sources and references: [5] [7]

Ask for a clear result from the assessment

A review may conclude that you are ready to proceed, that more information or treatment is needed first, or that another approach fits better. Ask the team to identify the specific reason and the next action. For example, an infection may need treatment, a pathology result may need confirmation or the proposed product may not match the disease.

If a clinical trial is suggested, request its identifier and entry criteria. Ask which tests determine eligibility and whether the site is currently screening. This lets you compare a research option with the established treatments available at the same point.

Sources and references: [8] [5]

Prepare an efficient Shanghai eligibility review

EastMedGo can help organize the documents for a CAR-T assessment and coordinate an appointment request in Shanghai. Ruijin Hospital is one hematology resource in the city; the proposed product and disease determine which service should review your case.

Start by contacting us with the diagnosis, age, treatment timeline and current disease status. We can help clarify missing records and practical requirements before you make travel commitments. After the hospital review, we can assist with the appointment sequence and questions about local stay, caregiver support and follow-up.

Sources and references: [9]

Common questions